Affiliations 

  • 1 Hospital Umum Sarawak, Ministry of Health, Jalan Hospital, Kuching, Sarawak, 93586, Malaysia
  • 2 Clinical Research Centre, Institute for Clinical Research, Hospital Umum Sarawak, Ministry of Health, Jalan Hospital, Kuching, Sarawak, 93586, Malaysia
  • 3 Hospital Kuala Lumpur, Ministry of Health, Jalan Pahang, Kuala Lumpur, 50586, Malaysia
  • 4 Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, 610 University Ave, Toronto, Ontario, M2G 2C1, Canada
  • 5 Clinical Research Malaysia, D-26-06, Menara Suezcap 1, KL Gateway, 2, Jalan Kerinchi, Kuala Lumpur, Federal Territory of Kuala Lumpur, 59200, Malaysia
  • 6 The Office of Director General, Ministry of Health, Putrajaya, Federal Territory of Putrajaya, 62590, Malaysia
Asia Pac J Clin Oncol, 2023 Jun;19(3):296-304.
PMID: 36305522 DOI: 10.1111/ajco.13886

Abstract

Historically, the majority of oncology clinical trials are conducted in Western Europe and North America. Globalization of drug development has resulted in sponsors shifting their focus to the Asia-Pacific region. In Malaysia, implementation of various government policies to promote clinical trials has been initiated over a decade ago and includes the establishment of Clinical Research Malaysia, which functions as a facilitator and enabler of industry-sponsored clinical trials on a nationwide basis. Although oncology clinical trials in Malaysia have seen promising growth, there are still only a limited number of early phase oncology studies being conducted. Hence, the Phase 1 Realization Project was initiated to develop Malaysia's early phase clinical trial capabilities. In addition, the adaptation of good practices from other countries contribute to the effective implementation of existing initiatives to drive progress in the development of early phase drug development set up in Malaysia. Furthermore, holistic approaches with emphasis in training and education, infrastructure capacities, strategic alliances, reinforcement of upstream activities in the value chain of drug development, enhanced patient advocacy, coupled with continued commitment from policy makers are imperative in nurturing a resilient clinical research ecosystem in Malaysia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.